Literature DB >> 12805466

Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene.

Danilo R Casimiro1, Aimin Tang, Ling Chen, Tong-Ming Fu, Robert K Evans, Mary-Ellen Davies, Daniel C Freed, William Hurni, Jose M Aste-Amezaga, Liming Guan, Romnie Long, Lingyi Huang, Virginia Harris, Denise K Nawrocki, Henryk Mach, Robert D Troutman, Lynne A Isopi, Krishna K Murthy, Karen Rice, Keith A Wilson, David B Volkin, Emilio A Emini, John W Shiver.   

Abstract

The cellular immunogenicity of formulated plasmid DNA and replication-defective human adenovirus serotype 5 (Ad5) vaccine vectors expressing a codon-optimized human immunodeficiency virus type 1 gag gene was examined in baboons. The Ad5 vaccine was capable of inducing consistently strong, long-lived CD8(+)-biased T-cell responses and in vitro cytotoxic activities. The DNA vaccine-elicited immune responses were weaker than those elicited by the Ad5 vaccine and highly variable; formulation with chemical adjuvants led to moderate increases in the levels of Gag-specific T cells. Increasing the DNA-primed responses with booster doses of either Ad5 or modified vaccinia virus Ankara vaccines suggests a difference in the relative levels of cytotoxic and helper responses. The implications of these results are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12805466      PMCID: PMC164828          DOI: 10.1128/jvi.77.13.7663-7668.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

2.  Differential expression of natural killer cell markers: human versus baboon.

Authors:  A M Malyguine; S Saadi; J L Platt; J R Dawson
Journal:  Transplantation       Date:  1996-11-15       Impact factor: 4.939

3.  Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Authors:  I Ourmanov; C R Brown; B Moss; M Carroll; L Wyatt; L Pletneva; S Goldstein; D Venzon; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Overcoming immunity to a viral vaccine by DNA priming before vector boosting.

Authors:  Zhi-yong Yang; Linda S Wyatt; Wing-Pui Kong; Zoe Moodie; Bernard Moss; Gary J Nabel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

Review 6.  Baboons as an animal model for human immunodeficiency virus pathogenesis and vaccine development.

Authors:  C P Locher; S A Witt; B G Herndier; K Tenner-Racz; P Racz; J A Levy
Journal:  Immunol Rev       Date:  2001-10       Impact factor: 12.988

7.  Evaluation of cytotoxic T-lymphocyte responses in human and nonhuman primate subjects infected with human immunodeficiency virus type 1 or simian/human immunodeficiency virus.

Authors:  T M Fu; D C Freed; W L Trigona; L Guan; L Zhu; R Long; N V Persaud; K Manson; S Dubey; J W Shiver
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines.

Authors:  Michael J Caulfield; Su Wang; Jeffrey G Smith; Timothy W Tobery; Xu Liu; Mary-Ellen Davies; Danilo R Casimiro; Tong-Ming Fu; Adam Simon; Robert K Evans; Emilio A Emini; John Shiver
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Authors:  Danilo R Casimiro; Ling Chen; Tong-Ming Fu; Robert K Evans; Michael J Caulfield; Mary-Ellen Davies; Aimin Tang; Minchun Chen; Lingyi Huang; Virginia Harris; Daniel C Freed; Keith A Wilson; Sheri Dubey; De-Min Zhu; Denise Nawrocki; Henryk Mach; Robert Troutman; Lynne Isopi; Donna Williams; William Hurni; Zheng Xu; Jeffrey G Smith; Su Wang; Xu Liu; Liming Guan; Romnie Long; Wendy Trigona; Gwendolyn J Heidecker; Helen C Perry; Natasha Persaud; Timothy J Toner; Qin Su; Xiaoping Liang; Rima Youil; Michael Chastain; Andrew J Bett; David B Volkin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques.

Authors:  Zdenek Hel; Janos Nacsa; Wen-Po Tsai; Arthur Thornton; Laura Giuliani; James Tartaglia; Genoveffa Franchini
Journal:  Virology       Date:  2002-12-05       Impact factor: 3.616

View more
  29 in total

Review 1.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

2.  Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Authors:  John R Mascola; Anna Sambor; Kristin Beaudry; Sampa Santra; Brent Welcher; Mark K Louder; Thomas C Vancott; Yue Huang; Bimal K Chakrabarti; Wing-Pui Kong; Zhi-Yong Yang; Ling Xu; David C Montefiori; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice.

Authors:  Lijun Xiao; Dimin Wang; Caijun Sun; Pingchao Li; Yi Jin; Liqiang Feng; Ling Chen
Journal:  Hum Vaccin Immunother       Date:  2013-12-10       Impact factor: 3.452

4.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Authors:  Glenda E Gray; Zoe Moodie; Barbara Metch; Peter B Gilbert; Linda-Gail Bekker; Gavin Churchyard; Maphoshane Nchabeleng; Koleka Mlisana; Fatima Laher; Surita Roux; Kathryn Mngadi; Craig Innes; Matsontso Mathebula; Mary Allen; M Julie McElrath; Michael Robertson; James Kublin; Lawrence Corey
Journal:  Lancet Infect Dis       Date:  2014-02-20       Impact factor: 25.071

5.  Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.

Authors:  Jianping Lin; Yan Zhi; Lauren Mays; James M Wilson
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

6.  Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines.

Authors:  Eric A Weaver; Pramod N Nehete; Bharti P Nehete; Stephanie J Buchl; Donna Palmer; David C Montefiori; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

7.  Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Authors:  Gerald K Chege; Wendy A Burgers; Helen Stutz; Ann E Meyers; Rosamund Chapman; Agano Kiravu; Rubina Bunjun; Enid G Shephard; William R Jacobs; Edward P Rybicki; Anna-Lise Williamson
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

8.  Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.

Authors:  Danilo R Casimiro; Andrew J Bett; Tong-ming Fu; Mary-Ellen Davies; Aimin Tang; Keith A Wilson; Minchun Chen; Romnie Long; Troy McKelvey; Michael Chastain; Sanjay Gurunathan; Jim Tartaglia; Emilio A Emini; John Shiver
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  Baculovirus vectors elicit antigen-specific immune responses in mice.

Authors:  Andrea Facciabene; Luigi Aurisicchio; Nicola La Monica
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

10.  Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines.

Authors:  Eric A Weaver; Pramod N Nehete; Stephanie S Buchl; Julien S Senac; Donna Palmer; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.